Invivo Therapeutics Holdings Corp Company Profile (OTCMKTS:NVIV)

About Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)

Invivo Therapeutics Holdings Corp logoInVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:NVIV
  • CUSIP: N/A
  • Web: www.invivotherapeutics.com/
Capitalization:
  • Market Cap: $45.06 million
  • Outstanding Shares: 32,185,000
Average Prices:
  • 50 Day Moving Avg: $1.34
  • 200 Day Moving Avg: $2.58
  • 52 Week Range: $1.10 - $6.97
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.19
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.59 per share
  • Price / Book: 2.37
Profitability:
  • EBIDTA: ($25,770,000.00)
  • Return on Equity: -118.45%
  • Return on Assets: -96.82%
Misc:
  • Average Volume: 407,656 shs.
  • Short Ratio: 8.76
 

Frequently Asked Questions for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)

What is Invivo Therapeutics Holdings Corp's stock symbol?

Invivo Therapeutics Holdings Corp trades on the OTCMKTS under the ticker symbol "NVIV."

How were Invivo Therapeutics Holdings Corp's earnings last quarter?

Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) posted its quarterly earnings results on Friday, November, 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.02. During the same quarter last year, the business posted ($0.22) earnings per share. View Invivo Therapeutics Holdings Corp's Earnings History.

When will Invivo Therapeutics Holdings Corp make its next earnings announcement?

Invivo Therapeutics Holdings Corp is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Invivo Therapeutics Holdings Corp.

Where is Invivo Therapeutics Holdings Corp's stock going? Where will Invivo Therapeutics Holdings Corp's stock price be in 2017?

1 analysts have issued 1 year target prices for Invivo Therapeutics Holdings Corp's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Invivo Therapeutics Holdings Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Invivo Therapeutics Holdings Corp.

Who are some of Invivo Therapeutics Holdings Corp's key competitors?

Who are Invivo Therapeutics Holdings Corp's key executives?

Invivo Therapeutics Holdings Corp's management team includes the folowing people:

  • Mark D. Perrin, Chairman of the Board, Chief Executive Officer
  • Christopher McNulty, Principal Financial Officer and Principal Accounting Officer
  • Melanie Morel-Ferris, Senior Director, Finance and Controller
  • Tamara L. Joseph J.D., Senior Vice President, Chief Compliance Officer, General Counsel
  • Thomas R. Ulich M.D., Chief Scientific Officer
  • Pamela J. Stahl, Chief Commercial Officer
  • Richard Toselli M.D., Chief Medical Officer
  • Ann Merrifield, Lead Independent Director
  • Jeffrey S. Hatfield, Director
  • Christina T. Morrison, Director

Who owns Invivo Therapeutics Holdings Corp stock?

Invivo Therapeutics Holdings Corp's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.88%), Legal & General Group Plc (1.57%), Welch & Forbes LLC (1.25%), IMS Capital Management (1.22%), State Street Corp (1.20%) and Goldman Sachs Group Inc. (0.52%). View Institutional Ownership Trends for Invivo Therapeutics Holdings Corp.

Who sold Invivo Therapeutics Holdings Corp stock? Who is selling Invivo Therapeutics Holdings Corp stock?

Invivo Therapeutics Holdings Corp's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., Welch & Forbes LLC, State Street Corp, IMS Capital Management, Boston Financial Mangement LLC and Stifel Financial Corp. View Insider Buying and Selling for Invivo Therapeutics Holdings Corp.

Who bought Invivo Therapeutics Holdings Corp stock? Who is buying Invivo Therapeutics Holdings Corp stock?

Invivo Therapeutics Holdings Corp's stock was purchased by a variety of institutional investors in the last quarter, including Legal & General Group Plc, Susquehanna International Group LLP, Goldman Sachs Group Inc., Blair William & Co. IL and LMR Partners LLP. View Insider Buying and Selling for Invivo Therapeutics Holdings Corp.

How do I buy Invivo Therapeutics Holdings Corp stock?

Shares of Invivo Therapeutics Holdings Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invivo Therapeutics Holdings Corp's stock price today?

One share of Invivo Therapeutics Holdings Corp stock can currently be purchased for approximately $1.40.


MarketBeat Community Rating for Invivo Therapeutics Holdings Corp (OTCMKTS NVIV)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics Holdings Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.00

Analysts' Ratings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Show:
DateFirmActionRatingPrice TargetDetails
7/31/2017Raymond James Financial, Inc.DowngradeOutperform -> Market PerformView Rating Details
7/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$23.25View Rating Details
5/12/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Earnings by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Earnings History by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS NVIV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017($0.22)N/AView Earnings Details
11/4/2016Q3($0.20)($0.18)ViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.18)ViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.20)ViewN/AView Earnings Details
11/4/2015Q3 2015($0.20)($0.22)ViewN/AView Earnings Details
8/5/2015Q2 2015($0.18)($0.21)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.11)($0.22)ViewN/AView Earnings Details
3/17/2014($0.08)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Current Year EPS Consensus Estimate: $-0.78 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS

Dividends

Dividend History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Insider Trades by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Institutional Ownership by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Insider Trades by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2014Francis ReynoldsMajor ShareholderSell50,000$1.20$60,000.00View SEC Filing  
5/5/2014Francis ReynoldsMajor ShareholderSell37,500$1.87$70,125.00View SEC Filing  
4/30/2014Francis ReynoldsMajor ShareholderSell37,500$1.82$68,250.00View SEC Filing  
4/25/2014Francis ReynoldsMajor ShareholderSell50,000$1.52$76,000.00View SEC Filing  
4/21/2014Francis ReynoldsMajor ShareholderSell50,000$1.57$78,500.00View SEC Filing  
4/14/2014Francis ReynoldsMajor ShareholderSell37,500$1.63$61,125.00View SEC Filing  
4/9/2014Francis ReynoldsMajor ShareholderSell37,500$1.60$60,000.00View SEC Filing  
4/4/2014Francis ReynoldsMajor ShareholderSell25,000$1.71$42,750.00View SEC Filing  
4/2/2014Francis ReynoldsMajor ShareholderSell37,500$1.71$64,125.00View SEC Filing  
3/26/2014Francis ReynoldsMajor ShareholderSell47,900$1.80$86,220.00View SEC Filing  
3/21/2014Francis ReynoldsMajor ShareholderSell39,600$2.15$85,140.00View SEC Filing  
3/17/2014Francis ReynoldsMajor ShareholderSell37,500$2.44$91,500.00View SEC Filing  
3/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.33$87,375.00View SEC Filing  
3/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
3/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.49$93,375.00View SEC Filing  
2/28/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
2/26/2014Francis ReynoldsMajor ShareholderSell37,500$2.28$85,500.00View SEC Filing  
2/21/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/19/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
2/14/2014Francis ReynoldsMajor ShareholderSell25,000$2.24$56,000.00View SEC Filing  
2/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.25$84,375.00View SEC Filing  
2/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.21$82,875.00View SEC Filing  
1/31/2014Francis ReynoldsMajor ShareholderSell25,000$2.17$54,250.00View SEC Filing  
1/29/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/24/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
1/21/2014Francis ReynoldsMajor ShareholderSell37,500$2.36$88,500.00View SEC Filing  
1/15/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/10/2014Francis ReynoldsMajor ShareholderSell48,000$2.41$115,680.00View SEC Filing  
1/6/2014Francis ReynoldsMajor ShareholderSell36,000$2.28$82,080.00View SEC Filing  
12/31/2013Francis ReynoldsMajor ShareholderSell36,000$2.25$81,000.00View SEC Filing  
12/26/2013Francis ReynoldsMajor ShareholderSell36,000$1.99$71,640.00View SEC Filing  
12/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.96$47,040.00View SEC Filing  
12/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
12/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.80$43,200.00View SEC Filing  
12/11/2013Francis ReynoldsMajor ShareholderSell36,000$1.75$63,000.00View SEC Filing  
12/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.59$38,160.00View SEC Filing  
12/4/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
11/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.92$46,080.00View SEC Filing  
11/20/2013Francis ReynoldsMajor ShareholderSell36,000$1.95$70,200.00View SEC Filing  
11/13/2013Francis ReynoldsMajor ShareholderSell36,000$1.14$41,040.00View SEC Filing  
11/8/2013Francis ReynoldsMajor ShareholderSell24,000$1.11$26,640.00View SEC Filing  
11/6/2013Francis ReynoldsMajor ShareholderSell36,000$1.16$41,760.00View SEC Filing  
11/1/2013Francis ReynoldsMajor ShareholderSell24,000$1.16$27,840.00View SEC Filing  
10/30/2013Francis ReynoldsMajor ShareholderSell36,000$1.23$44,280.00View SEC Filing  
10/25/2013Francis ReynoldsMajor ShareholderSell24,000$1.35$32,400.00View SEC Filing  
10/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.40$33,600.00View SEC Filing  
10/18/2013Francis ReynoldsMajor ShareholderSell24,000$1.45$34,800.00View SEC Filing  
10/16/2013Francis ReynoldsMajor ShareholderSell36,000$1.49$53,640.00View SEC Filing  
10/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.51$36,240.00View SEC Filing  
10/9/2013Francis ReynoldsMajor ShareholderSell36,000$1.41$50,760.00View SEC Filing  
10/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.41$33,840.00View SEC Filing  
9/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.37$32,880.00View SEC Filing  
9/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.43$51,480.00View SEC Filing  
9/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.50$36,000.00View SEC Filing  
9/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.72$41,280.00View SEC Filing  
9/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.61$38,640.00View SEC Filing  
9/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.36$32,640.00View SEC Filing  
9/3/2013Sean F MoranCFOBuy20,000$1.02$20,400.00View SEC Filing  
8/30/2013Francis ReynoldsMajor ShareholderSell9,200$1.55$14,260.00View SEC Filing  
8/30/2013Sean F MoranCFOBuy40,000$1.30$52,000.00View SEC Filing  
8/28/2013Francis ReynoldsMajor ShareholderSell12,600$3.24$40,824.00View SEC Filing  
8/23/2013Francis ReynoldsMajor ShareholderSell21,300$4.07$86,691.00View SEC Filing  
8/21/2013Francis ReynoldsCEOSell36,000$4.12$148,320.00View SEC Filing  
8/16/2013Francis ReynoldsCEOSell24,000$4.24$101,760.00View SEC Filing  
8/14/2013Francis ReynoldsCEOSell36,000$4.34$156,240.00View SEC Filing  
8/9/2013Francis ReynoldsCEOSell24,000$4.42$106,080.00View SEC Filing  
8/7/2013Francis ReynoldsCEOSell36,000$4.46$160,560.00View SEC Filing  
8/2/2013Francis ReynoldsCEOSell24,000$4.57$109,680.00View SEC Filing  
7/30/2013Francis ReynoldsCEOSell24,000$5.11$122,640.00View SEC Filing  
7/26/2013Francis ReynoldsCEOSell24,000$5.29$126,960.00View SEC Filing  
7/24/2013Francis ReynoldsCEOSell36,000$5.72$205,920.00View SEC Filing  
7/19/2013Francis ReynoldsCEOSell24,000$5.27$126,480.00View SEC Filing  
7/17/2013Francis ReynoldsCEOSell36,000$5.12$184,320.00View SEC Filing  
7/12/2013Francis ReynoldsCEOSell24,000$4.43$106,320.00View SEC Filing  
7/10/2013Francis ReynoldsCEOSell36,000$3.97$142,920.00View SEC Filing  
7/5/2013Francis ReynoldsCEOSell12,000$4.00$48,000.00View SEC Filing  
7/3/2013Francis ReynoldsCEOSell36,000$4.08$146,880.00View SEC Filing  
6/28/2013Francis ReynoldsCEOSell24,000$4.22$101,280.00View SEC Filing  
6/26/2013Francis ReynoldsCEOSell36,000$3.87$139,320.00View SEC Filing  
6/21/2013Francis ReynoldsCEOSell24,000$3.78$90,720.00View SEC Filing  
6/19/2013Francis ReynoldsCEOSell36,000$3.89$140,040.00View SEC Filing  
6/14/2013Francis ReynoldsCEOSell24,000$3.84$92,160.00View SEC Filing  
6/12/2013Francis ReynoldsCEOSell12,750$4.34$55,335.00View SEC Filing  
6/7/2013Francis ReynoldsCEOSell8,500$4.02$34,170.00View SEC Filing  
6/5/2013Francis ReynoldsCEOSell12,750$3.75$47,812.50View SEC Filing  
6/5/2013Robert LangerMajor ShareholderSell7,500$3.73$27,975.00View SEC Filing  
5/31/2013Francis ReynoldsCEOSell8,500$3.32$28,220.00View SEC Filing  
5/31/2013Robert LangerMajor ShareholderSell7,500$3.31$24,825.00View SEC Filing  
5/29/2013Francis ReynoldsCEOSell8,500$3.13$26,605.00View SEC Filing  
5/28/2013Robert LangerMajor ShareholderSell7,500$2.97$22,275.00View SEC Filing  
5/24/2013Francis ReynoldsCEOSell8,500$2.95$25,075.00View SEC Filing  
5/22/2013Robert LangerMajor ShareholderSell7,500$2.88$21,600.00View SEC Filing  
5/21/2013Francis ReynoldsCEOSell12,750$2.88$36,720.00View SEC Filing  
5/17/2013Francis ReynoldsCEOSell8,500$2.87$24,395.00View SEC Filing  
5/17/2013Robert LangerMajor ShareholderSell7,500$2.85$21,375.00View SEC Filing  
5/15/2013Francis ReynoldsCEOSell12,750$2.89$36,847.50View SEC Filing  
5/14/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
5/10/2013Francis ReynoldsCEOSell8,500$2.92$24,820.00View SEC Filing  
5/9/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
4/12/2013Francis ReynoldsCEOSell8,500$3.16$26,860.00View SEC Filing  
2/5/2013Francis ReynoldsCEOSell12,750$2.03$25,882.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Latest Headlines for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Source:
DateHeadline
businesswire.com logoInVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference - Business Wire (press release)
www.businesswire.com - September 22 at 11:58 AM
finance.yahoo.com logoInVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 22 at 11:58 AM
businesswire.com logoInVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord ... - Business Wire (press release)
www.businesswire.com - September 6 at 7:00 AM
finance.yahoo.com logoInVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade
finance.yahoo.com - September 6 at 6:59 AM
americanbankingnews.com logoValuEngine Lowers Invivo Therapeutics Holdings Corp (NVIV) to Strong Sell
www.americanbankingnews.com - September 2 at 8:14 PM
finance.yahoo.com logoInVivo slashes staff and ousts science chief
finance.yahoo.com - August 30 at 7:23 AM
businesswire.com logoInVivo Therapeutics Announces Strategic Corporate Restructuring - Business Wire (press release)
www.businesswire.com - August 29 at 6:11 AM
finance.yahoo.com logoInVivo Therapeutics Announces Strategic Corporate Restructuring
finance.yahoo.com - August 29 at 6:11 AM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (OTCMKTS:NVIV) and Viveve Medical (VIVE) Head to Head Survey
www.americanbankingnews.com - August 12 at 2:14 AM
streetinsider.com logoInvivo Therapeutics (NVIV) Reports Exchange of Certain Warrants for Common Stock
www.streetinsider.com - August 11 at 7:08 AM
finance.yahoo.com logoInVivo Therapeutics Announces Exchange of Certain Warrants for Common Stock
finance.yahoo.com - August 11 at 7:08 AM
reuters.com logoBRIEF-InVivo Therapeutics Holdings Q2 adjusted loss per share $0.22 excluding items
www.reuters.com - August 9 at 5:41 AM
finance.yahoo.com logoInVivo Therapeutics to Present at Canaccord Genuity’s 37th Annual Growth Conference
finance.yahoo.com - August 9 at 5:40 AM
finance.yahoo.com logoInVivo Therapeutics Provides Business Update and Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 9 at 5:40 AM
finance.yahoo.com logoInVivo reports 2Q loss
finance.yahoo.com - August 9 at 5:40 AM
seekingalpha.com logoThird Trial Death Endangers Invivo - Seeking Alpha
seekingalpha.com - August 3 at 6:27 AM
businesswire.com logoInVivo Therapeutics Announces Updates on the INSPIRE Study - Business Wire (press release)
www.businesswire.com - July 31 at 11:32 PM
finance.yahoo.com logoInVivo Therapeutics Announces Updates on the INSPIRE Study
finance.yahoo.com - July 31 at 11:32 PM
finance.yahoo.com logoInVivo halts trial of spine injury treatment after third patient dies
finance.yahoo.com - July 31 at 11:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of InVivo Therapeutics Holding Corp. - NVIV
finance.yahoo.com - July 31 at 11:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of InVivo Therapeutics Holding Corp. (NVIV)
finance.yahoo.com - July 31 at 11:32 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Lowered to "Market Perform" at Raymond James Financial, Inc.
www.americanbankingnews.com - July 31 at 5:31 PM
businesswire.com logoInVivo Therapeutics Announces Stanford Medicine as New Site for INSPIRE Study - Business Wire (press release)
www.businesswire.com - July 13 at 7:28 AM
businesswire.com logoInVivo Therapeutics Opens First Site in the United Kingdom for INSPIRE Study - Business Wire (press release)
www.businesswire.com - July 13 at 7:28 AM
finance.yahoo.com logoInVivo Therapeutics Announces Stanford Medicine as New Site for INSPIRE Study
finance.yahoo.com - July 13 at 7:28 AM
finance.yahoo.com logoInVivo Therapeutics Opens First Site in the United Kingdom for INSPIRE Study
finance.yahoo.com - July 12 at 6:29 AM
reuters.com logoBRIEF-Invivo Therapeutics appoints Richard Toselli as chief medical officer
www.reuters.com - July 11 at 6:05 AM
finance.yahoo.com logoInVivo Therapeutics Appoints Richard Toselli, M.D. as Chief Medical Officer
finance.yahoo.com - July 11 at 6:05 AM
businesswire.com logoInVivo Therapeutics Announces UCHealth Memorial Hospital as New Site for INSPIRE Study - Business Wire (press release)
www.businesswire.com - July 1 at 5:49 AM
finance.yahoo.com logoInVivo Therapeutics Announces UCHealth Memorial Hospital as New Site for INSPIRE Study
finance.yahoo.com - June 30 at 2:41 AM
streetinsider.com logoInvivo Therapeutics (NVIV) Reports Positive Motor Recovery Assessments in Two Patients in INSPIRE Study
www.streetinsider.com - June 28 at 1:35 PM
finance.yahoo.com logoInVivo Therapeutics Announces Positive Motor Recovery Assessments in Two Patients in the INSPIRE Study of the Neuro-Spinal Scaffold™
finance.yahoo.com - June 28 at 1:35 PM
businesswire.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital - Business Wire (press release)
www.businesswire.com - June 27 at 7:03 PM
finance.yahoo.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital
finance.yahoo.com - June 27 at 7:03 PM
businesswire.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Allegheny General Hospital - Business Wire (press release)
www.businesswire.com - June 21 at 8:14 PM
nasdaq.com logoMid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge - Nasdaq
www.nasdaq.com - June 21 at 8:14 PM
feeds.benzinga.com logo10 Biggest Mid-Day Gainers For Tuesday
feeds.benzinga.com - June 20 at 1:25 PM
businesswire.com logoInVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference - Business Wire (press release)
www.businesswire.com - June 13 at 9:39 AM
finance.yahoo.com logoInVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference
finance.yahoo.com - June 12 at 8:47 AM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Downgraded by ValuEngine
www.americanbankingnews.com - June 3 at 10:40 PM
businesswire.com logoInVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting - Business Wire (press release)
www.businesswire.com - June 1 at 8:52 AM
finance.yahoo.com logoInVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting
finance.yahoo.com - June 1 at 8:52 AM
reuters.com logoBRIEF-InVivo Therapeutics announces update to the contemporary Thoracic SCI Registry Study
www.reuters.com - May 30 at 6:40 PM
businesswire.com logoInVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry ... - Business Wire (press release)
www.businesswire.com - May 30 at 9:19 AM
finance.yahoo.com logoInVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”)
finance.yahoo.com - May 30 at 9:19 AM
businesswire.com logoInVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury ... - Business Wire (press release)
www.businesswire.com - May 11 at 9:16 AM
finance.yahoo.com logoInVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting
finance.yahoo.com - May 9 at 11:26 AM
businesswire.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science ... - Business Wire (press release)
www.businesswire.com - May 8 at 12:14 PM
finance.yahoo.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University
finance.yahoo.com - May 8 at 12:14 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Given Outperform Rating at Raymond James Financial, Inc.
www.americanbankingnews.com - May 5 at 10:36 AM

Social

Chart

Invivo Therapeutics Holdings Corp (NVIV) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff